These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39248222)

  • 21. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
    Rupprecht E; König E; Limmer J
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
    [No Abstract]   [Full Text] [Related]  

  • 22. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
    Raee MR; Nargesi AA; Heidari B; Mansournia MA; Larry M; Rabizadeh S; Zarifkar M; Esteghamati A; Nakhjavani M
    Arch Iran Med; 2017 Mar; 20(3):141-146. PubMed ID: 28287807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.
    Fisman EZ; Tenenbaum A; Boyko V; Benderly M; Adler Y; Friedensohn A; Kohanovski M; Rotzak R; Schneider H; Behar S; Motro M
    Clin Cardiol; 2001 Feb; 24(2):151-8. PubMed ID: 11460818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
    Harrower AD
    Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
    Cho EH; Han K; Kim B; Lee DH
    Medicine (Baltimore); 2020 Jul; 99(29):e21236. PubMed ID: 32702900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of gliclazide and left ventricular mass in type 2 diabetic patients.
    Pan NH; Lee TM; Lin MS; Huang CL; Chang NC
    Diabetes Res Clin Pract; 2006 Nov; 74(2):121-8. PubMed ID: 16631274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of different sulfonylureas on the warm-up phenomenon in diabetes patients with coronary artery disease].
    Zheng M; Li LZ; Jiang ZA; Li LH; Feng YG; Fu XH
    Zhonghua Yi Xue Za Zhi; 2017 Jan; 97(3):198-202. PubMed ID: 28162170
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.
    Harrower AD
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S65-7. PubMed ID: 1794268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Drug Saf; 2013 Aug; 36(8):605-15. PubMed ID: 23700263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Yu LW; Ko GT; Kong AP; Ng VW; Luk AO; Ozaki R; Tong PC; Chow CC; Chan JC
    Diabetes Res Clin Pract; 2010 Dec; 90(3):343-51. PubMed ID: 20889221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide.
    Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
    Can J Diabetes; 2015 Nov; 39 Suppl 4():32-40. PubMed ID: 26541489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin.
    Monami M; Luzzi C; Lamanna C; Chiasserini V; Addante F; Desideri CM; Masotti G; Marchionni N; Mannucci E
    Diabetes Metab Res Rev; 2006; 22(6):477-82. PubMed ID: 16634115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.